

Table S2. IFN- γ responses in EHC +ve (EC-01 to EC-20), active VL (VL-1 to VL-8) and EHC-ve (EC-42 to EC-50) individuals at 72 hours after stimulation of whole blood *ex vivo* with candidate vaccine antigens (peptide pools; 5 μ g/mL), SLA (10 μ g/mL), PPD (5 μ g/mL), or mitogen PHA (5 μ g/mL). IFN- γ levels were measured by ELISA.

Mitogen or Leishmania Antigen													
ID	PHA	SLA	R71	Q51	L37	N52	L302. 06	J89	M18	J41	M22	M63	M57
			100%	100%	99%	94%	90%	87%	78%	73%	61%	54%	35%
EC-01	+++++	+	-	+	+	+	-	-	+	+	-	+	+
EC-02	+++++	++++	-	-	-	-	-	-	+	-	+	-	-
EC-03	+++++	++++	-	-	+	-	-	-	-	-	-	-	-
EC-04	+++++	+++	+	-	+	+	+	+	-	-	-	+	-
EC-05	+++++	+++	-	-	+	-	-	-	-	+	-	-	-
EC-06	+++++	+++	+	-	++	+	-	-	-	+	-	-	-
EC-07	+++++	+	++	-	+	+	-	-	-	+	+	-	-
EC-08	+++++	+++	++	-	-	+	-	-	-	-	-	-	-
EC-09	+++++	+++	+	-	+	+	-	-	-	+	+	-	-
EC-10	+++++	+++	++	-	+	-	-	-	-	+	+	-	-
EC-11	+++++	+++	-	-	-	++	-	-	-	-	-	-	-
EC-12	+++++	+++	++	-	+++	-	-	-	-	+	+	-	-
EC-13	+++++	+++	-	++	-	-	-	-	-	-	-	-	-
EC-14	+++++	+++	+	-	+	+	-	-	-	+	-	-	-
EC-15	+++++	+++	-	-	+	-	-	-	-	+	-	-	-
EC-16	+++++	+++	+	+	++	++	+	-	-	+	+	-	-
EC-17	+++++	+++	-	-	-	+	+	-	-	+	-	-	-
EC-18	+++++	+	+	-	-	-	-	-	-	-	+	-	-
EC-19	+++++	++	+	-	+	++	-	-	-	+	+	-	-
EC-20	+++++	-	+	+	-	-	-	-	-	-	-	-	-
♦♦	100%	95 %	60%	20%	65%	55%	15%	5%	10%	60%	40%	10%	5%
VL-1	+++++	++	+	+	++	+	-	+	+	+	+	+	-
VL-2	+++++	+	-	-	-	-	-	+	-	-	-	-	-
VL-3	+++++	++	+	-	++	-	-	+	+	+	+	+	-
VL-4	+++	++	-	-	-	-	-	-	-	-	-	+	-
VL-5	+++++	++	-	-	-	-	-	-	-	-	-	-	-
VL-6	+++++	++	+	-	-	-	++	-	-	-	-	-	-
VL-7	+++++	+	-	-	+	-	-	-	-	-	-	+	-
VL-8	+++	+	-	-	-	-	-	-	-	-	-	-	-
♦♦	100%	100%	37%	12%	37%	12%	12%	37.5 %	28.6 %	25%	25%	50%	0%
EC-42	+++++	-	+	-	+	-	-	-	-	-	-	+	-
EC-43	+++	-	+	-	+	+	+	+	-	+	+	+	-
EC-44	+++	-	-	-	-	+	-	-	+	-	+	+	-
EC-45	+++	-	+	-	+	-	-	-	-	+	+	+	-
EC-46	++	-	-	-	-	-	-	-	-	-	-	-	+
EC-47	+++	-	-	-	-	-	-	+	-	-	-	-	-
EC-48	+++	-	-	-	-	-	-	-	-	-	-	-	-
EC-49	+++	-	-	-	-	-	-	-	-	-	-	-	-
EC-50	++	-	-	+	-	-	-	-	-	-	-	+	-
♦♦	100%	0%	33%	11%	33%	22%	11%	22%	11%	22%	33%	55%	11%

- = <20pg/ml; + = 20-100pg/ml; ++ = 100-250; +++ = 250-500pg/ml; ++++ = 500-10000pg/ml; +++++ = >10000pg/ml;

PHA = Phytohaemagglutinin; PPD = purified protein derivative from *Mycobacterium tuberculosis*; SLA = Soluble

Leishmania antigen. ♦♦ indicates percent of responders to each antigen in each study group. Percent identity with *L. infantum* sequence at the amino acid level is indicated in the row below candidate vaccine antigens (R71, Q51, etc.), which were originally derived from *L. major* [1].

1. Stober CB, Lange UG, Roberts MT, Gilmartin B, Francis R, et al. (2006) From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 24: 2602-2616.